ClinicalTrials.gg
WithdrawnNCT00384657Updated Dec 22, 2017

Intravenous Iron in Patients With Severe Chronic Heart Failure and Chronic Kidney Disease

A Phase 3 interventional study of iron sucrose in Chronic Kidney Disease, Chronic Heart Failure and Anemia, sponsored by Anemia Working Group Romania. Withdrawn at 2 sites in Romania. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-12-22.

Sponsored by Anemia Working Group Romania · Phase 3, Interventional, and Treatment

How we know

Why this study was withdrawn
Lack of cooperation among centers, Financial reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Renal Insufficiency, Chronic with a site in Romania — 8 open to participants now, 11 under way, 7 of them phase 3. Renal Insufficiency, Chronic · Romania.

Enrollment
55th of 56
0 · median 455
Started
2008
with 4 others
Phase 3
40 of 65
4 open now
Registered
2nd of 65
by date
Lead sponsor
4 of 65
Anemia Working Group Romania

Among the 65 studies in Renal Insufficiency, Chronic with a site in Romania, this one is the 55th largest by enrollment of the 56 interventional ones that give a count, is one of 5 that started in 2008, is one of 40 in phase 3, and was the 2nd registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

8 of the 65 studies in Renal Insufficiency, Chronic with a site in Romania are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Romania have not opened yet or have stopped. Only those recruiting at a site in Romania →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Renal Insufficiency, Chronic with a site in Romania, or all of them as a file.
02

Study summary

Recently, growing body of evidence support the finding that anemia frequently occurs in patients with chronic heart failure (CHF). Chronic kidney disease (CKD), as well, is highly prevalent among heart failure patients, and both anemia and CKD are independently associated with increased mortality. A vicious circle is established with CHF causing both chronic renal insufficiency and anemia, and CKD further aggravating anemia which, in turn, worsens CHF and so on. Treatment of the anemia breaks this circle and improves the quality of life, cardiac and renal functions in patients with severe CHF.

Intravenous iron alone was proved to allow the maintenance of target hematocrit in one-third of chronic renal failure predialysis patients.

Based on these considerations, intravenous iron for anemia in patients with CHF and moderate CKD would represent a reasonable therapeutic approach.

The aim of the trial is to assess the efficiency of intravenous iron therapy in the management of mild to moderate anemia associated with CHF NYHA III class and concomitant moderate CKD.

Read the detailed description

Intravenous iron administration in CHF patients with absolute or functional iron deficiency could correct their anemia, thus improving cardiac function judged by ejection fraction and NYHA functional class. If true, enhancement of cardiac output will increase oxygen delivery to tissues, including renal cortex. This might improve the renal functions and slow the rate of progression of CKD reflected by the slope of decline in glomerular filtration rate (GFR).

Since erythropoietin synthesis is located in peritubular fibroblasts from outer renal cortex, which is the most affected area during chronic hypoxia, increasing renal blood flow after anemia correction is expected to restore optimal erythropoietin production and normalize plasma Epo levels.

The primary objective is to assess the efficiency of intravenous iron therapy in the management of mild to moderate anemia associated with chronic heart failure NYHA III class and concomitant moderate chronic kidney disease.

The secondary objectives are to determine if the correction of anemia in these patients affects the cardiac function, the rate of progression of CKD and the plasma erythropoietin levels.

The study will be conducted in accordance with the Declaration from Helsinki and Tokyo, with the amendments from Venice (1983), after the approval by the local ethics committee.

The total observation period will be of 28 weeks, with a pre-study phase (selection, randomization of subjects) 4 weeks.The study period will last 24 weeks, with a possible extension to 48 weeks, depending on the results of this first phase.

200 anemic patients with chronic heart failure class NYHA III and concomitant stage 3 chronic kidney disease will be enrolled, after obtaining their written informed consent.

All patients will be evaluated for the inclusion and exclusion criteria at enrollment and at each visit during the pre-study phase. Only patients fulfilling all the requested criteria at all evaluation moments will be enrolled. The enrolled subjects will be centrally randomly assigned in a 1:1 ratio into two study groups.

Group I (treatment group): Subjects assigned to this group will receive intravenous iron (ferric sucrose product Venofer® 2%, 5mL/ampoule) in a starting dose of 200mg (2 ampoules) diluted in 150mL 0.9% NaCl solution, over 60 minutes, once a week for the first four administrations, and then every other week until hemoglobin levels reach 12g/dL. Then, iron dose will be adjusted to 1 ampoule at 2-4 weeks interval, as needed to maintain these levels with serum ferritin ≤500ng/mL.

Iron administration will be discontinued if serum ferritin will exceed 500ng/mL, and will be restarted with a reduced dosage (1 ampoule at every 2-4 weeks) once serum ferritin decrease below this value.

Conventional treatment for CHF will be continued as needed. Group II (control group): Subjects assigned to this group will continue their conventional treatment for CHF as needed, without iron supplementation.

No other anti-anemic medication will be administered in either group during the study period.

Subject's visits will take place at two weeks intervals in the first 12 weeks of the study phase and at 4 weeks apart thereafter. At each visit will be recorded, according to the schedule, data concerning physical examination, including signs of CHF, hematological and iron status, renal function, concomitant medication and adverse events.

Parameters recorded at the time of first iron administration will serve as baseline determination.

The completion of the study will be declared when 200 subjects will complete the whole observation period, according to the above protocol.

03

Conditions studied

  • Chronic Kidney Disease
  • Chronic Heart Failure
  • Anemia

Keywords

  • chronic heart failure
  • chronic kidney disease
  • anemia
  • intravenous iron
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • persistent severe CHF: functional class III (marked limitation of physical activity - comfortable at rest, but less than ordinary activity results in shortness of breath and/or fatigue16); (echocardiography) less than 40%; functional and systolic dysfunction criteria must be stable at two different examinations one month apart;
  • stable stage 3 chronic kidney disease: estimated between 30-59mL/min/1.73m2 (mean value of three measurements within the last 8 weeks, separated from each other by at least one week); stable renal function (at least three different measurements within the past 8 weeks, separated from each other by at least one week; the difference between the highest and the lowest value should be less than 5mL/min/1.73m2)
  • mild to moderate anemia: levels \< 12g/dL (mean value of three measurements within the last 8 weeks, separated from each other by at least one week) and stable (at least three measurements within the last 8 weeks; the difference between the highest and the lowest value should be less than 1.5g/dL);
  • iron deficiency: absolute (serum ferritin \< 100ng/mL) or functional (serum ferritin 100-300ng/mL and transferrin saturation \< 20%)

Exclusion criteria

Exclusion Criteria:

  • evidence of active gastrointestinal or genital tract bleeding
  • folate or vitamin B12 deficiency
  • hypothyroidism
  • hemolytic anemia
  • any primary kidney diseases (glomerulonephritis, interstitial nephritis, cystic diseases)
  • systemic diseases with renal involvement (lupus erythematosus, vasculitis, amyloidosis)
  • renal artery stenosis (>70% lumen reduction)
  • diabetic nephropathy
  • severe malnutrition (SGA score C or lower)
  • active liver diseases
  • infectious conditions
  • C-reactive protein > 12 mg/L
  • severe anemia (\< 8.5g/dL)
  • blood transfusions in the preceding two months
  • iron therapy in the preceding three months
  • concomitant erythropoietin therapy
  • severe arterial hypertension (systolic BP >190 mm Hg and/or diastolic BP >115 mm Hg)
  • recent history (less than 3 months) of acute coronary syndrome
  • recent (less than 1 month) PCI
  • recent (less than 1 month) CABG surgery
  • active myocarditis
  • active endocarditis
  • more than mild valvar stenosis
  • more than moderate valvar (mitral or aortic) regurgitation
  • uncontrolled haemodynamically relevant atrial fibrillation/flutter
  • hypertrophic cardiomyopathy
  • acute and/or chronic pericarditis
  • cor pulmonale
  • participation in another study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Group I

    iv iron sucrose

    Drug: iron sucrose

  • No intervention
    Group II

    Patients will receive conventional treatment of Chronic Heart Failure.

Interventions

  • Patients in Group I will receive iv iron sucrose, as described in the study protocol. Patient in Group II will receive conventional treatment for chronic heart failure.

    Also known as: Group I - iv iron group, Group II - conventional treatment group

06

What researchers measure

Primary outcomes

  1. percentage of patients with increased ejection fraction

    Time frame: 12 months

Secondary outcomes

  1. the need for blood transfusions during the study period

    Time frame: 12 months

  2. serum ferritin level

    Time frame: 12 months

  3. transferrin saturation

    Time frame: 12 months

  4. radial myocardial velocities

    Time frame: 12 months

  5. right ventricular function

    Time frame: 12 months

  6. global diastolic function

    Time frame: 12 months

  7. left ventricular mass index

    Time frame: 12 months

  8. major cardiovascular events (myocardial infarction, acute pulmonary edema, stroke)

    Time frame: 12 months

  9. hospital admissions

    Time frame: 12 months

  10. death of the patient (all causes deaths, cardiac deaths)

    Time frame: 12 months

  11. slope of GFR change

    Time frame: 12 months

  12. "death" of the kidney (initiation of renal replacement therapy)

    Time frame: 12 months

07

Study locations

2 sites
  • "Dr Carol Davila" Teaching Hospital of Nephrology
    Bucharest, 010731, Romania
  • "Caritas" Teaching Hospital, Cardiology Department
    Bucharest, Romania
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2008 to primary completion in Dec 2017, 119 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2006
First posted
Oct 6, 2006
StartActual
Jan 2008
Primary completionActual
Dec 2017
CompletionActual
Dec 2017
Last update
Dec 22, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00384657
Lead sponsor
Anemia Working Group Romania
Responsible party
Liliana Garneata (Dr, Anemia Working Group Romania) — Principal investigator
First posted
Oct 6, 2006
Start date
Jan 2008
Primary completion
Dec 2017
Completion
Dec 2017
Last update
Dec 22, 2017

Study contacts

Gabriel Mircescu, Professor
study director · Dr Carol Davila Teaching Hospital of Nephrology
Tiberiu Nanea, Professor
principal investigator · "Caritas" Teaching Hospital, Bucharest
Liliana Garneata, MD, PhD
principal investigator · Dr Carol Davila Teaching Hospital of Nephrology Bucharest

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron sucrose

Start the discussion